Misinformation regarding PAR and another Focalin ANDA was posted on IHUB
PAR may file their own Focalin ANDA, but the agreement states that they would still share profits of their ANDA with IPCI, so IPCI would get revenue from the PAR focalin - which hasn't been approved yet anyway so the point is mute.
The pps not down because of that post. It is down because the biotech market is being sold off and investors are giving little weight to pipelines and looking only at earnings that they can rely on. Luckily we have some, but it has only been one quarter.
I agree this is a sector thing and likely has nothing to do with message board rumors. Take a look at other small cap bios for the last couple weeks. IPCI has really weathered this storm better than most.